Abstract
Multiple coactivator and corepressor complexes play an important role in endocrine processes and breast cancer; in particular, estrogen and estrogen receptor-α (ERα) promote the proliferation of breast cancer cells. Menin is a tumor suppressor encoded by Men1 that is mutated in the human-inherited tumor syndrome multiple endocrine neoplasia type 1 (MEN1); it also serves as a critical link in the recruitment of nuclear receptor-mediated transcription. Here, we show that menin expressed in breast cancer cell line MCF-7 is colocalized with ERα and functions as a direct coactivator of ER-mediated transcription in breast cancer cells. In MCF-7 cells, coexpression of menin and estrogen-response element-luciferase induced the activity of the latter in a hormone-dependent manner. Cells knocked down for ERα exhibited impaired ERE-luciferase activity induced by menin. Mammalian two-hybrid assay and GST pull-down assays indicated that menin could interact with the AF-2 domain of ERα. These results indicate that menin is a direct activator of ERα function. Tamoxifen inhibited the binding of menin to AF-2 in mammalian two-hybrid assay, but in menin-overexpressing clones, tamoxifen suppressed ERE-luciferase activity only to the levels of nontreated wild-type MCF-7. In a clinical study with 65 ER-positive breast cancer samples—all of which had been treated with tamoxifen for 2–5 years as adjuvant therapies—menin-positive tumors had a worse outcome than menin-negative ones. These indicated that menin can function as a transcriptional regulator of ERα and is a possible predictive factor for tamoxifen resistance.






Similar content being viewed by others
References
Ciocca DR, Fanelli MA (1997) Estrogen receptors and cell proliferation in breast cancer. Trends Endocrinol Metab 8:313–821
Govind AP, Thampan RV (2001) Proteins interacting with the mammalian estrogen receptor: proposal for an integrated model for estrogen receptor mediated regulation of transcription. J Cell Biochem 80:571–579
Fishman J, Osborne MP, Telang NT (1995) The role of estrogen in mammary carcinogenesis. Ann NY Acad Sci 768:91–100
Davidson NE (2000) Combined endocrine therapy for breast cancer—new life for an old idea? J Natl Cancer Inst 92:859–860
Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339:974–984
Chen JD, Evans RM (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454–457
Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733–736
Heinzel T, Lavinsky RM, Mullen TM, Söderstrom M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG (1997) A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43–48
McKenna NJ, Lanz RB, O’Malley BW (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 2:321–344
Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373–380
Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM (1997) Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569–580
McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME (1999) P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA 96:5383–5387
Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, Buisson N, De Witte K, Salandre J, Lenoir G, Pugeat M, Calender A, Parente F, Quincey D, Gaudray P, De Wit MJ, Lips CJ, Höppener JW, Khodaei S, Grant AL, Weber G, Kytölä S, Teh BT, Farnebo F, Phelan C, Hayward N, Larsson N, Pannett AAJ, Forbes SA, Bassett JHD, Thakker RV (1997) Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum Mol Genet 6:1177–1183
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404–407
Sheppherd JJ (1991) The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized? Arch Surg 126:935–952
Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O’Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A, Thakker RV (1996) Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Q J Med 89:653–659
Poisson A, Zablewska B, Gaudray P (2003) Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1. Cancer Lett 189:1–10
Chandrasekharappa SC, Teh BT (2003) Functional studies of the MEN1 gene. J Intern Med 253:606–615
Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, Hickman AB, Cerrato A, Rice TS, Moore JB, Rao S, Ji Y, Mateo C, Libutti SK, Oliver B, Chandrasekharappa SC, Burns AL, Collins FS, Spiegel AM, Marx SJ (2005) Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res 37:369–374
Sayo Y, Murao K, Imachi H, Cao WM, Sato M, Dobashi H, Wong NC, Ishida T (2002) The multiple endocrine neoplasia type 1 gene product, menin, inhibits insulin production in rat insulinoma cells. Endocrinology 143:2437–2440
Schnepp RW, Mao H, Sykes SM, Zong WX, Silva A, La P, Hua X (2004) Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem 279:10685–10691
Busygina V, Suphapeetiporn K, Marek LR, Stowers RS, Xu T, Bale AE (2004) Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum Mol Genet 13:2399–2408
Jin S, Mao H, Schnepp RW, Sykes SM, Silva AC, D’Andrea AD, Hua X (2003) Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 63:4204–4210
Scappaticci S, Maraschio P, del Ciotto N, Fossati GS, Zonta A, Fraccaro M (1991) Chromosome abnormalities in lymphocytes and fibroblasts of subjects with multiple endocrine neoplasia type 1. Cancer Genet Cytogenet 52:85–92
Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL (1999) Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96:143–152
Heppner C, Bilimoria KY, Agarwal SK, Kester M, Whitty LJ, Guru SC, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL (2001) The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 20:4917–4925
Lin S, Elledge SJ (2003) Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113:881–889
Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Hess JL, Meyerson M (2004) Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 13:587–597
Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, Herr W, Cleary ML (2004) Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 24:5639–5649
Bhuiyan MM, Sato M, Murao K, Imachi H, Namihira H, Takahara J (2000) Expression of menin in parathyroid tumors. J Clin Endocrinol Metab 85:2615–2619
Bhuiyan MM, Sato M, Murao K, Imachi H, Namihira H, Ishida T, Takahara J, Miyauchi A (2001) Differential expression of menin in various adrenal tumors. The role of menin in adrenal tumors. Cancer 92:1393–1401
Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y, Saji S, Hayashi S (2001) MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem Biophys Res Commun 281:259–265
Sakamoto T, Eguchi H, Omoto Y, Ayabe T, Mori H, Hayashi S (2002) Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol Cell Endocrinol 192:93–104
Murao K, Wada Y, Nakamura T, Taylor AH, Mooradian AD, Wong NC (1998) Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J Biol Chem 273:18959–18965
Murao K, Terpstra V, Green SR, Kondratenko N, Steinberg D, Quehenberger O (1997) Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem 272:17551–17557
Hayashi S, Hajiro-Nakanishi K, Makino Y, Eguchi H, Yodoi J, Tanaka H (1997) Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Nucleic Acids Res 25:4035–4040
Murao K, Bassyouni H, Taylor AH, Wanke IE, Wong NC (1997) Hepatocyte nuclear factor 4 inhibits activity of site A from the rat apolipoprotein A1 gene. Biochemistry 36:301–306
Namihira H, Sato M, Murao K, Cao WM, Matsubara S, Imachi H, Niimi M, Dobashi H, Wong NC, Ishida T (2002) The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. J Mol Endocrinol 29:297–304
Dreijerink KM, Mulder KW, Winkler GS, Höppener JW, Lips CJ, Timmers HT (2006) Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res 66:4929–4935
Sato M, Matsubara S, Miyauchi A, Ohye H, Imachi H, Murao K, Takahara J (1998) Identification of five novel germline mutations of the MEN1 gene in Japanese multiple endocrine neoplasia type 1 (MEN1) families. J Med Genet 35:915–919
Berry M, Metzger D, Chambon P (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811–2818
Shupnik MA, Pitt LK, Soh AY, Anderson A, Lopes MB, Laws ER Jr (1998) Selective expression of estrogen receptor alpha and beta isoforms in human pituitary tumors. J Clin Endocrinol Metab 83:3965–3972
Glass CK, Rose DW, Rosenfeld MG (1997) Nuclear receptor coactivators. Curr Opin Cell Biol 9:222–232
McInerney EM, Tsai MJ, O’Malley BW, Katzenellenbogen BS (1996) Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci USA 93:10069–10073
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968
Katzenellenbogen BS, Katzenellenbogen JA (2002) Biomedicine. Defining the “S” in SERMs. Science 295:2380–2381
Katzenellenbogen JA, O’Malley BW, Katzenellenbogen BS (1996) Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 10:119–131
Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW (1998) Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95:2920–2925
Métivier R, Stark A, Flouriot G, Hübner MR, Brand H, Penot G, Manu D, Denger S, Reid G, Kos M, Russell RB, Kah O, Pakdel F, Gannon F (2002) A dynamic structural model for estrogen receptor-alpha activation by ligands, emphasizing the role of interactions between distant A and E domains. Mol Cell 10:1019–1032
Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA (2001) Mechanisms of estrogen action. Physiol Rev 81:1535–1565
Norris JD, Fan D, Sherk A, McDonnell DP (2002) A negative coregulator for the human ER. Mol Endocrinol 16:459–468
Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB (1997) The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693–705
Fox EM, Davis RJ, Shupnik MA (2008) ERbeta in breast cancer—onlooker, passive player, or active protector? Steroids 73:1039–1051
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll J (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663–667
Friedl P, Wolf K (2008) Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res 68:7247–7249
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174
Itoh Y (2006) MT1-MMP: a key regulator of cell migration in tissue. IUBMB Life 58:589–596
Kousidou OCh, Berdiaki A, Kletsas D, Zafiropoulos A, Theocharis AD, Tzanakakis GN, Karamanos NK (2008) Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol 2:223–232
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Imachi, H., Murao, K., Dobashi, H. et al. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Breast Cancer Res Treat 122, 395–407 (2010). https://doi.org/10.1007/s10549-009-0581-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-009-0581-0